Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

A large, well-controlled phase 2 RCT in which semaglutide is a core study arm, not an incidental mention. The combination with zalfermin failed to beat placebo on the fibrosis endpoint, but semaglutide 2.4 mg alone was associated with a nominally significant improvement, prompting the authors to flag it for further study in the F4c cirrhosis population. Gastrointestinal adverse events were common, consistent with the known profile.